Health Canada adds five ingredients to the Prescription Drug List
In this article & details
Health Canada added five medicinal ingredients to the federal Prescription Drug List (PDL) in a notice posted October 29. The additions take effect immediately. The notice covers camizestrant; donidalorsen and its salts; zongertinib and its salts; and sodium benzoate and sodium phenylacetate when used together to lower blood ammonia.
The decision matters to pharmacy teams because the PDL identifies drugs that require a prescription for sale in Canada. It is a regulatory classification—not a notice that every product containing a newly listed ingredient has received marketing authorization, is being sold, or is covered by a public drug plan. Product authorization and current marketed status should be checked separately in Health Canada’s Drug Product Database, while reimbursement is determined by the relevant provincial, territorial or private plan.
What the notice lists
- Camizestrant, identified by Health Canada with the brand Etcamah, is described for use with a CDK4/6 inhibitor in a specific group of adults with advanced or metastatic hormone-receptor-positive, HER2-negative breast cancer after an ESR1 mutation is detected during first-line aromatase-inhibitor therapy.
- Donidalorsen (Dawnzera) is described for prevention of hereditary-angioedema attacks in adults and children aged 12 and older.
- Zongertinib (Hernexeos) is described for adults with unresectable or metastatic non-small-cell lung cancer with specified HER2 mutations after prior systemic therapy.
- Sodium benzoate and sodium phenylacetate are included only when used together to reduce ammonia in the blood. Health Canada describes the combination product Ammivo as adjunctive treatment for acute hyperammonemia in children and adults with urea-cycle enzyme deficiencies.
These descriptions explain the products named in the notice; they are not a substitute for the Canadian product monograph, nor do they establish that a particular presentation is stocked locally.
Why prescription status is separate from approval
Health Canada says the additions follow a scientific review under the Food and Drug Regulations’ prescription-status criteria. That review addresses whether a drug should be sold only on prescription. A Notice of Compliance and Drug Identification Number are separate regulatory steps for a specific product. A listing on the PDL should therefore not be read on its own as confirmation that a new drug can already be ordered or dispensed.
For pharmacists and pharmacy managers, the practical point is to check the exact ingredient, salt, combination qualifier and product status when reviewing a new or unfamiliar item. The ammonia-lowering ingredients have a defined combination condition; the notice does not make every product containing sodium benzoate or sodium phenylacetate prescription-only without qualification.
Health Canada’s notice gives the effective date as the date of posting—October 29, 2026. For individual product approval, labelling and market status, consult the Drug Product Database and current Canadian product monograph. Public-plan coverage is a separate question and may differ by jurisdiction.
A date distinction for Hernexeos
The distinction is visible in Health Canada’s own records: its NOC/c listing records Hernexeos’ conditional market authorization as issued September 24, 2026, while the PDL amendment is dated October 29. The current item is therefore the prescription-status update, not a new approval announcement for zongertinib. For other listed ingredients, readers should check the product-level database rather than infer approval dates from the PDL notice.
